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Since January of 2010, the seventh edition of UICC tumor node metastasis (TNM) Classification, which has recently been revised, has 
been applied to almost all cases of malignant tumors. Compared to previous editions, the merits and demerits of the current revisions 
were analyzed. Many revisions have been made for criteria for the classification of lymph nodes. In particular, all the cases in whom the 
number of lymph nodes is more than 7 were classified as N3 without being differentiated. Therefore, the coverage of the N3 was broad. 
Owing to this, there was no consistency in predicting the prognosis of the N3 group. By determining the positive cases to a distant me-
tastasis as TNM stage IV, the discrepancy in the TNM stage IV compared to the sixth edition was resolved. In regard to the classification 
system for an esophagogastric (EG) junction carcinoma, it was declared that cases of an invasion to the EG junction should follow the 
classification system for esophageal cancer. A review of clinical cases reported from Asian patients suggests that it would be more appro-
priate to follow the previous editions of the classification system for gastric cancer. In addition, in the classification of the TNM stages in 
the overall cases, the discrepancy in the prognosis between the different stages and the consistency in the prognosis between the same 
TNM stages were achieved to a lesser extent as compared to that previously. Accordingly, further revisions are needed to develop a pur-
posive classification method where the prognosis can be predicted specifically to each variable and the mode of the overall classification 
can be simplified.
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Introduction
Tumor node metastasis (TNM) staging provides guidance for 
selecting the optimal treatment modalities. It also provides infor-
mation on the prognosis for both physicians and patients. Further-
more, it is also used as a tool by which the treatment outcomes can 
be compared at hospitals and in different countries.
Disease staging based on the TNM classification currently 
provides a basis for staging almost all cases of a malignant tumor. 
This staging method is amended continuously and revised over time 
 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/3.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
as new diagnostic or treatment methods have been developed. In 
the disease staging system, it is essential to determine if consistency 
can be acquired between the groups for which the same disease 
stage was determined and how the differentiation could be made 
between groups for which a different disease stage was determined. 
In addition, the applicability should be considered from a practical 
perspective. That is, it would be ideal to develop the staging system 
in such a manner that the specificity to each category should be 
assured and the overall classification should be simplified. In this 
regard, this study assessed the seventh edition of TNM staging. 
The TNM staging for gastric cancer has been included in the first 
edition of UICC TNM since 1966.(1) Since January, 2010, the 
revised seventh edition has been used. A review of the revisions 
on the seventh edition of TNM staging focused mainly on the 
classification of lymph nodes. In particular, changes were made for 
the fifth edition published in 1997 compared to previous editions. 
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In other words, it was recommended that lymph nodes be classified 
based on the anatomical location. On the other hand, the fifth 
edition recommends that the lymph nodes be classified based on 
the number of lymph nodes with a metastasis. Major revisions on 
the current seventh edition include the following:
(1) Changes in the methods for classifying lymph nodes
(2) Changes in the definition of TNM stage IV
(3) Changes in the application of the disease staging to the eso-
phago-gastric junction
(4) The classification of positive cases to a peritoneal washing 
cytology to a distant metastasis. 
Given this background, this study analyzed the significance of 
these changes and examined the matters that need to be considered 
in the future classification of the disease stage.
The Scope of the Classification of  
Lymph Nodes with Metastasis
A revision was made for the definitions on the seventh edition 
when they were based on the number of lymph nodes observed 
on the fifth and the sixth edition. In other words, in the seventh 
edition, which unlike the previous classifications in that the number 
of lymph nodes with a metastasis of 1~6, 7~15 and ≥16 were 
classified as N1, N2 and N3, respectively, those in which the 
number of lymph nodes with a metastasis was 1~2, 3~6, 7~15 and 
≥16 were classified as N1, N2, N3a and N3b, respectively. N3a 
and N3b were classified as the same stage. According to Ha et 
al.,(2) there was a significant difference in the survival rate between 
N3a and N3b. In particular, in the seventh edition, all cases with 
a metastasis in more than 7 lymph nodes were classified as N3. 
Compared to N1 or N2, there was a wider standard deviation in 
the number of lymph nodes with a metastasis (N1: 0.49, N2: 1.10 
and N3: 13.77). This indicates that there is great variability in the 
number of lymph nodes with a metastasis in patients who belong to 
the N3 group. Based on the cut-off value of the number of lymph 
nodes with a metastasis of 30, N3 was subclassified into N3a (the 
number of lymph nodes with metastasis: 7~15), N3b (the number 
of lymph nodes with metastasis: 16~30) and N3c (the number 
of lymph nodes with metastasis: ≥31). This was followed by an 
analysis of the survival rate between the three subgroups in those 
patients with TanyN3M0. This showed that there was a significant 
difference in the survival rate between the three groups (P＜0.0001). 
In addition, following a comparison of the survival rate between 
the TanyN3cM0 group and stage IV based on the degree of the 
invasion to the gastric wall, there was a significant difference in the 
survival rate between T3N3cM0 and stage IV and that between 
T4aN3cM0 and stage IV (P=0.044 and P=0.007, respectively). On 
the other hand, there was no significant difference in the survival 
rate between T4bN3cM0 and stage IV. In other words, T4bN3cM0 
was classified as stage IIIc in the seventh edition but it was found 
to be too poor to have a significant difference in the survival rate 
compared to stage IV. As described herein, there was no significant 
difference in the survival rate, even though there was a significant 
difference and the other disease stages were determined, even in 
cases for which the same disease stage was determined on the 
TNM staging system in the seventh edition (In press). According 
to Huang et al.,(3) few cases with early-stage gastric cancer had 
more than 6 lymph nodes with a metastasis. These authors reported 
that there were almost no cases corresponding to N2 (7~15) and 
N3 (＞15) based on the TNM staging on the fifth edition. They 
also noted that the difference in survival rate between N2 and N3 
was significant after re-classifying N into N1 (1~3), N2 (4~6) and 
N3 (＞6), even though there was no significant difference in the 
survival rate between N2 and N3. This point of view was reflected 
appropriately in the seventh edition of TNM staging. If one should 
analyze these study results, he or she would be skeptical about 
whether there would be a difference in the methods for applying 
the TNM staging to progressive gastric cancer and early-stage 
gastric cancer. Some reports have shown that the classification 
of lymph nodes proposed on the seventh edition was better in 
predicting the prognosis compared to the sixth edition(4-6) but 
there are also dissenting reports.(2,7) A further subclassification 
of the lymph nodes would be useful for predicting the prognosis 
of each case. Other aspects are present that would cause many 
problems with clinical applications due to a very complicated 
staging system. In consideration of this, further studies will be 
needed to develop a staging system by harmonizing the two aspects 
that classifications should be made more specifically and then be 
uncomplicated.
The Number of Lymph Nodes  
That Were Dissected
The sixth edition of UICC TNM staging system declared that a 
pathological examination should be performed to make an accurate 
assessment of the degree of lymph node metastasis in more than 
15 lymph nodes. According to the seventh edition, based on the 
statement “Any cases in whom no metastases are detected in all Kwon SJ
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the lymph nodes with no respect to the number of lymph nodes 
dissected, even though the number of dissected lymph nodes was 
no greater than 16, could be classified as N0 group”, revisions were 
made in that the dissection of more than 16 lymph nodes would 
not be mandatory (the classification is pNo if the examined lymph 
nodes are negative but the number ordinarily resected is not met.). 
Previous studies reported contradictory results in that correct disease 
staging could become difficult due to stage migration in cases in 
whom the number of dissected lymph nodes was insufficient.(8,9) 
Based on these revisions, stage migration could occur in many 
cases. According to Hundahl et al.,(10) based on the disease staging 
performed for cases of gastric cancer surgery in North America, the 
proportion of those with more than 15 lymph nodes dissected was 
at most 18%. One study examined the validity of staging for cases 
of esophagogastric (EG) junction cancer through a comparison 
between the adequate staging group where more than 15 lymph 
nodes were dissected and an inadequate staging group where less 
than 15 lymph nodes had been dissected.(11) They reported that 
the TNM staging could be performed accurately only in cases in 
whom more than 15 lymph nodes had been dissected. In particular, 
this would make it possible to accurately predict the prognosis of 
patients with progressive gastric cancer. According to INT-0116(12) 
and MAGIC Trial,(13) both of which were large-scale, randomized 
clinical studies conducted in America and Europe, the proportion 
of cases in whom a more extensive D2 lymph node dissection 
was performed was 10% and 41.4%, respectively. In addition, the 
proportion of cases in whom the D0 lymph node dissection, i.e., a 
less D1 lymph node dissection, was performed on 54% and 15.1%, 
respectively. According to ACTS-GC, a prospective, in randomized 
clinical study recently conducted in Japan, 99.8% of cases had a D2 
lymph node dissection. This is contradictory to the above reports.
Of the total cases of gastric cancer surgery, which was 
performed at large-volume centers in Korea and the USA, the 
proportion of those in which less than 15 lymph nodes were 
dissected was 3% and 22%, respectively. A comparison of the 
survival rate of patients between the two hospitals during the same 
disease duration revealed the survival rates of patients with stage 
I/II/III to be significantly higher in Korea compared to USA.(14) 
One of the major causes of these results might be stage migration 
resulting from an insufficient lymph node dissection. 
In cases in whom the dissection of more than 15 lymph 
nodes is an essential condition for the TNM staging, it might be 
impossible to determine the TNM stage in many patients from the 
USA and Europe. The current guidelines might have been loosened 
considering this in the seventh edition. In a future TNM staging 
system, the untoward effects called ‘a lower standardization’ can 
be prevented provided it is specified as the essential condition for 
TNM staging that more than 16 lymph nodes should be dissected.
The Proportion of Lymph Nodes  
with Metastasis
 In the UICC and AJCC TNM Classification, the cuff-off point 
of the scope of lymph nodes with a metastasis has been revised 
continuously. To date, its gold standard has not been identified. 
Given this background, the proportion of lymph nodes with a 
metastasis relative to the number of dissected lymph nodes was 
divided into several segments. Some suggest that it should be used 
as a tool for assessing the degree of lymph node metastasis.(15-
17) In addition, the proportion of lymph nodes with a metastasis 
exceeds the ability to predict the prognosis based on the pre-
existing TNM Classification, even in cases of breast cancer, colon 
cancer and rectal cancer.(18-20) As reported by Lemmens et 
al.,(21) the proportion of lymph nodes with a metastasis was first 
proposed as a measure to overcome the limitations of a lymph 
node dissection. The methods for screening the lymph nodes with 
a metastasis were once assessed as the best tool for predicting the 
prognosis. This might not be superior to the classification based on 
the N category due to reasons such as the limitation in the number 
of dissected lymph nodes, the insufficiency in a consensus on 
the segment interval and the insufficiency in a consensus on the 
scope of lymph node metastasis. In cases for which surgery was 
performed with a smaller number of dissected lymph nodes in the 
USA and Europe, it might also be a good method that can be used 
alternatively to the pre-existing TNM classification.
Constituents Forming the TNM Stage IV
In the sixth edition, the TNM stage IV included M0 and 
M1, which showed a significant difference in the survival rate. 
Considering this, several authors reported that staging should be 
done in such a manner that stage IV should be differentiated into 
stages IV a and IVb according to M0 or M1.(22-25) Given this 
background, in the seventh edition, only distant metastasis-positive 
cases (M1) were classified as stage IV. Although there are many 
lymph nodes with a metastasis or the degree of invasion to the 
gastric wall is as high as possible, the corresponding cases were 
classified as stages other than stage IV. Therefore, differentiation Evaluation of the 7th UICC TNM Staging System of Gastric Cancer
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of the survival rate in stage IV cases was strengthened. Of the total 
M0 cases, no stage IV was determined in cases in whom both the 
degree of invasion to the gastric wall and that of a lymph node 
metastasis were relatively higher. The difference in the survival 
rate from stage IV would not be of statistical significance. As 
mentioned previously, highly-advanced T4b cases in whom the 
number of lymph nodes with a metastasis was greater than 30 were 
not classified as stage IV provided there was M0. Compared to 
the cases in whom stage IV was determined, a poorer prognosis 
was found. In these cases, a more advanced classification system 
is needed. Another classification system is a revision that positive 
cases to a peritoneal washing cytology are classified as a distant 
metastasis. There are various methods for performing a peritoneal 
washing cytology. Depending on the types of methods, there is 
a large discrepancy in the frequency of a positive cytology (cy+). 
According to Kodera et al.,(26) the rate of positive cases was found 
＞20% on a routine cytology, 35% on immunohistochemistry 
and 50% on RT-PCR in cases of a serosa invasion-positive 
gastric carcinoma. In addition, there is a large discrepancy in the 
positive rates and median survival time (MST) of the positive 
cases between institutions. At the East Hospital of National Cancer 
Center of Japan, the positive rate and MST were 14% and 12 
months, respectively, in cases of invasion to the subserosal layer 
or deeper (n=924). At the Central Hospital of National Cancer 
Center of Japan,(27) the positive rate and MST were 22.6% and 
12 months, respectively, in cases of invasion to the muscular layer 
or deeper (n=996). At the MD Anderson Cancer Center in the 
USA,(28) the positive rate was 10.2% in cases of T1~T4b (n=381). 
After classifying these cases into the neoadjuvant chemotherapy 
group and non-neoadjuvant chemotherapy group, the MST was 
found to be 13 months and 7 months, respectively. According to 
reports from the Queen Elizabeth Hospital in the UK,(29) in 207 
cases of T3 and T4a, the positive rate and MST were 7.2% and 13 
months, respectively. Indeed, a peritoneal washing cytology is not a 
diagnostic regimen that is commonly performed at most hospitals. 
Accordingly, there should be guidelines for recording whether a 
cytology was performed, e.g. CYX. On the seventh edition of the 
UICC TNM staging system, positive cases to a peritoneal washing 
cytology are classified as a distant metastasis, except for which 
there are no definite guidelines for recording whether the cytology 
should be performed. Accordingly, if there are any positive cases in 
whom a peritoneal washing cytology was not performed and there 
was no concurrent presence of other lesions of a distant metastasis, 
these cases are not classified as stage IV. This might cause problems 
in establishing consistency between the TNM stages. According 
to the methods of the tests and because of the variability in the 
interpretation of test results, further revisions will be needed to 
examine whether a peritoneal washing cytology can be classified as 
a distant metastasis.
The TNM Staging in the EG Junction 
Carcinoma
According to W ashington,(30) because there is variability in the 
prognosis of gastric cancer depending on the anatomical location at 
the sites of occurrence, cancers at the distal sites have a better 
prognosis. Accordingly, there is the possibility that the classification 
system developed the most appropriately for cancers at the distal 
sites might not be the best TNM staging. Accordingly, in an effort 
to improve the staging system for gastric cancer, only when the 
data obtained from Asians and Caucasians are referenced can the 
classification be applied from a worldwide perspective. In particular, 
regarding cases of the EG junction carcinoma, according to the 
sixth edition, based on the judgment of the physicians, classifica-
tions into the esophageal cancer or gastric cancer should be made. 
In the seventh edition, however, the primary goal of revisions to 
the TNM staging was to clear this confusion. The secondary goal is 
to homogenize the tumor (T) category for cases of gastrointestinal 
tumors occurring at the gastrointestinal (GI) tract extending from 
the stomach, small intestine and large intestine to the rectum. 
Therefore, attempts were made to simply the concept of the T-
category, which is one of the essential factors for the classification 
of TNM stage. To achieve these goals, it was declared that the clas-
sification system for esophageal cancer be followed in cases of EG 
junction carcinoma and the previous confusion was resolved ac-
cordingly. On the other hand, there is no evidence demonstrating 
the validity of the application of the classification system for 
esophageal cancer rather than stomach cancer. Besides, there are 
reports that the same T category should be applied to all cancers 
occurring at this site because the GI tract is formed of a single tu-
bular structure. On the other hand, this would be problematic be-
cause the anatomical difference between the organs was not con-
sidered. According to Hassan et al.,(31) the incidence of gastric 
cardia adenocarcinoma was increased with time and increased 
gradually to 42% of the total cases of gastric cancer in 1996. Clark 
et al.(32) reported that the incidence of cardia cancer and that of 
distal esophageal adenocarcinoma in Caucasians had increased. 
This led to the speculation that both disease entities have the same Kwon SJ
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pathogenetic origins. Dolan et al.(33) reported a similarity in the 
etiology, epidemiology and clinicopathological features between an 
adenocarcinoma of lower esophagus and cardia. These authors re-
ported that these two carcinomas should be classified as the same 
disease entity. According to large-scale studies conducted on 1,002 
cases of the EG junction carcinoma, Rüdiger Siewert et al.(34) re-
ported that Type I (tumors with the center located from 5 cm to 1 
cm above the EG junction) formed a specific category that should 
be considered as a lower esophageal cancer and most of these cases 
occurred in the Barrett’s esophagus, which are the sites of intestinal 
dysplasia of the lower esophagus formed due to the EG regurgita-
tion. In contrast, in Type II cases (tumors with the center located 1 
cm above to 2 cm below the EG junction), the intestinal dysplasia 
formed in only 10% in the lower esophagus. In patients with Type 
III (tumors with the center located from 2 cm to 5 cm below the 
EG junction), the incidence of intestinal dysplasia was very low. 
Accordingly, there is great discrepancy between Type I cases. In 
other words, a Type II tumor is closer to gastric cancer at the prox-
imal sites than a lower esophageal adenocarcinoma. In addition, 
according to studies on the lymphatic circulation, the lymphatic 
ducts originating from the lower esophagus bilaterally progress, i.e. 
the mediastinum superiorly and the celiac axis inferiorly. In cases 
of Type II and III, most lymphatic ducts progress to the celiac axis. 
For this reason, there is a difference in the pattern of lymph node 
metastasis between Types II and I tumors, which is also similar to 
Type III. In cases of Type II tumor, the esophagectomy has not 
improved the survival rate compared to an extensive gastrectomy. 
According to Kusano et al.,(35) the incidence of an EG junction 
carcinoma (Siewert Type II) was 10% in patients with progressive 
gastric cancer who had been treated surgically at the National Can-
cer Center of Japan from 2001 to 2005 and the incidence of Siewert 
Type I was approximately 1%. According to studies comparing the 
characteristics of gastric cancer between Asians and Caucasians,(36) 
the incidence of an EG junction carcinoma was 0.4%, which is 
much lower than the 18% observed in Caucasians. In addition, fol-
lowing the classification of an EG junction carcinoma into Siwert 
Types I and II, there were almost no cases of Type I in Koreans.(37) 
The incidence of upper gastric 1/3 cancer steeply increased sharply 
to 12.5% up to 1992. Since then, its increasing rate has been re-
duced markedly and showed a greatly different tendency compared 
to the higher increasing rate observed in Caucasians.(38) According 
to the staging system on the seventh edition of the UICC TNM, 
cases in whom the central region of carcinoma was located within 
5 cm superior and inferior to the EG junction and then invaded the 
EG junction, were classified based on the classification system for 
esophageal cancer. To evaluate the validity of the changes in this 
classification system, 496 cases of an EG junction carcinoma were 
classified based on the classification system of esophageal cancer in 
the seventh edition at the Seoul National University Hospital. This 
was followed by an analysis of the difference in the survival rate 
between the stages. The survival rate was similar in stage I (n=230) 
and stage II (n=116) (P=0.948), but there was a significant differ-
ence in the survival rate between stages III (n=150) and II (P
＜0.001) and between stages III and I (P＜0.001). A comparative 
analysis of the survival rate between the TNM stages after the same 
patient group was classified based on the TNM staging revealed a 
difference in the survival rate between stage I (n=241) and stage II 
(n=125) at a moderate degree of statistical significance (P=0.089). In 
addition, there was a significant difference in the survival rate be-
tween stages III (n=130) and II (P＜0.001) and that between stages 
III and I (P＜0.001). This suggests that the classification system for 
gastric cancer rather than the classification system for esophageal 
cancer reflects the difference in the survival rate between the TNM 
stages. One study examined the survival rates between the TNM 
stages in 4,027 cases of gastric cancer located more than 5 cm distal 
to the EG junction and 496 cases of the EG junction carcinoma. A 
comparison of the survival rate between the TNM stages in cases 
of the EG junction carcinoma, which had been classified based on 
the classification system for esophageal cancer and that for gastric 
cancer between the TNM stages, revealed a significant difference 
in the survival rate in stage II patients (P=0.021). Nevertheless, there 
was no significant difference in the survival rate between all the 
TNM stages (stage I, stage II and stage III) in cases of the EG 
junction carcinoma, which had been classified based on the classi-
fication system for esophageal cancer and gastric cancers occurring 
at other sites. This suggests that the current revisions might fulfill 
the classification system for both cancers at distal and proximal 
sites. Based on these results, there is a higher degree of differences 
for EG junction carcinomas based on the classification system for 
gastric cancer rather than the classification system for esophageal 
cancer (not pressed). The Japanese Society for Gastric Cancer de-
fined carcinomas located within 2 cm superiorly and inferiorly to 
the EG junction as EG junction cancer in collaboration with the 
Japanese Society for Esophageal Cancer.(39) Controversial opinions 
exist regarding the treatment modalities for cases of EG junction 
cancer. Currently, there is some consensus that the optimal treat-
ment modalities should be selected based on the distance of tumor 
invasion to the stomach or esophagus rather than the location of Evaluation of the 7th UICC TNM Staging System of Gastric Cancer
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the central region of the tumor. According to the 83th workshop of 
the Japanese Society for Gastric Cancer, on March 2011, “Pro-
gresses in the diagnosis and treatment of the esophago-gastric 
junction tumors”, most Japanese surgeons considered an EG junc-
tion carcinoma to be a gastric cancer rather than an esophageal 
cancer for treatment. According to Rausei et al.,(40) EG junction 
carcinoma was included in the esophageal chapter based on the 
new TNM staging system according to the anatomical criteria ‘5 
cm rule’ proposed by Siewert but this was based on an obscure 
concept of the tumor epicenter. Accordingly in some cases, a gas-
tric fundus tumor might also be considered as an esophageal can-
cer. Therefore, the current revision did not clarify the clinical issues 
that are well known regarding the EG junction carcinoma. Never-
theless, it did not discourage attempts to make a differentiation of 
an EG junction carcinoma from an esophageal or gastric cancer.
Conclusions
In the seventh edition of the UICC TNM staging, which has 
recently been revised, attempts were made to resolve the problems 
of previous editions of TNM staging. On the other hand, any 
noticeable matters have not been resolved. First of all, the N3 
category was defined too extensively in the classification of lymph 
node metastasis. This achieved a simplification of the classification 
but it impaired the accuracy in predicting the prognosis in cases of 
progressive gastric cancer with a large number of lymph nodes with 
metastasis. Besides, it also did not clarify the minimum number of 
lymph nodes that should be dissected for appropriate TNM staging 
as shown previously. Therefore, it reduced the accuracy of TNM 
staging due to stage migration. Although it declared that it resolved 
the confusion of previous editions of TNM staging by specifying 
that the EG junction carcinoma should follow the classification 
system for esophageal cancer, it provided no clear evidence for this 
and did not resolve the previous issues. The edition also declared 
that positive cases to a peritoneal washing cytology should be 
considered a distant metastasis and then determined to be TNM 
stage IV. On the other hand, there are no standardized methods for 
this diagnostic regimen, which is not performed at many medical 
institutions, and deserves further consideration.
 The most ideal TNM staging methods should be composed 
of simpler rules so that it may be used easily in a clinical setting. 
Simultaneously, it should also guarantee the consistency between 
the cases corresponding to the same TNM stage and the 
differentiation between those corresponding to different TNM 
stages. This is quite challenging to surgeons. Further revisions of 
the TNM staging will be needed to contain both of these aspects to 
develop a harmonized classification.
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